XML 85 R44.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

INTANGIBLE ASSETS, NET (Details Narrative) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2019 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) |  | $ 78,864 |  |
Amortization of Intangible Assets |  | 197,593 | $ 112,474 | $ 71,516
Amortization of Other Deferred Charges |  | $ 778,692 |  |
Council License Agreement [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent |  | 50.00% |  |
Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent |  | 20.00% |  |
Required milestone payments upon cumulative net sales of specified levels |  | $ 40,000,000 |  |
Specified level one of cumulative net sales for required milestone payments |  | 200,000,000 |  |
Specified level two of cumulative net sales for required milestone payments |  | 400,000,000 |  |
Specified level three of cumulative net sales for required milestone payments |  | 1,000,000,000 |  |
Maximum costs and expenses for post approval |  | $ 20,000,000 |  |
Council License Agreement Step 1 |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Royalty (percent) |  | 5.00% |  |
Council License Agreement Step 1 | Maximum [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Net sales amount per step-based royalty |  | $ 50,000,000 |  |
Council License Agreement Step 2 |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Royalty (percent) |  | 10.00% |  |
Council License Agreement Step 2 | Maximum [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Net sales amount per step-based royalty |  | $ 150,000,000 |  |
Council License Agreement Step 2 | Minimum [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Net sales amount per step-based royalty |  | $ 50,000,000 |  |
Council License Agreement Step 3 |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Royalty (percent) |  | 15.00% |  |
Council License Agreement Step 3 | Minimum [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Net sales amount per step-based royalty |  | $ 150,000,000 |  |
ANNOVERA [Member] | Council License Agreement [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Milestone payment upon FDA Approval | $ 20,000,000 |  |  |
Milestone payments (payment after release of first commercial batch) | 20,000,000 |  |  |
License rights acquired | $ 20,000,000 |  |  |
Amortization of Other Deferred Charges |  | $ 778,692 |  |
Approved Hormone Therapy Drug Candidate Patents [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  | 20 years |  |
Domestic US Patents |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 29 |  |
Foreign Patents Member |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 30 |  |
Domestic Patents BIJUVA |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 12 |  |
Foreign Patents BIJUVA |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 6 |  |
Domestic Patents NonApproved BIJUVA |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 3 |  |
Domestic US Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 6 |  |
Domestic US Utility Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 5 |  |
Domestic US Design Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 1 |  |
Foreign Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 13 |  |
Foreign Utility Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 3 |  |
Foreign Design Patents IMVEXXY |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 10 |  |
Domestic US Patents Topical Cream |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 1 |  |
Domestic Utility Patent Transdermal Patch |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 1 |  |
Foreign Utility Patent Transdermal Patch |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 7 |  |
Domestic Utility Patent TX009HR |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 3 |  |
Domestic Patents Progesterone Formulations |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 2 |  |
Foreign Patents Progesterone Formulations |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 4 |  |
Domestic Utility Patent Opera |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Number of issued patents |  | 1 |  |

X
- Definition The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement. + References No definition available. + Details
Name: | txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payments upon FDA approval. + References No definition available. + Details
Name: | txmd_MilestonePaymentUponFDAApproval
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payments payable after release of first commercial batch. + References No definition available. + Details
Name: | txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The net sales amount as defined in license agreement for step-based royalty payments. + References No definition available. + Details
Name: | txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of issued patents. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatents
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of required milestone payments upon cumulative net sales of specified levels by the company and affiliates and permitted sublicensees. + References No definition available. + Details
Name: | txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percent of the net sales to be paid as royalty per license agreement. + References No definition available. + Details
Name: | txmd_RoyaltyPercent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The first level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments. + References No definition available. + Details
Name: | txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The third level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments. + References No definition available. + Details
Name: | txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The second level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments. + References No definition available. + Details
Name: | txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of amortization of other deferred costs recognized in the income statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_OtherAmortizationOfDeferredCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsTopicalCreamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |